Methylation profiling

Dataset Information

0

Durable HTT silencing using non-evolved dCas9 epigenome editors in patient-derived cells


ABSTRACT: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a trinucleotide repeat expansion in exon 1 of the huntingtin (HTT) gene. Nuclease-deficient Cas9 protein (dCas9) epigenetic editing for targeted gene regulation is a promising therapeutic approach for HD through downregulation of the causative gene, HTT. A screen of several dCas9 variants with expanded PAM recognition was fused to KRAB and DNMT3A/L to assess the ability to downregulate total HTT. Surprisingly, only SpdCas9 could significantly downregulate HTT, while expanded PAM recognition variants dxCas9 and dCas9-VQR were less efficient or unable to reduce HTT expression. Using our lead construct with SpdCas9, DNA methylation changes were assessed through reduced representation bisulfite sequencing, showing high on-target increases in DNA methylation and few off-targets. In addition, HTT silencing was mitotically stable for up to 6 weeks in a rapidly dividing cell line. Finally, significant downregulation of HTT was achieved in patient-derived neuronal stem cells, showing the efficacy of this system in a disease-relevant cell type. This approach represents a novel therapeutic pathway for the treatment of HD.

ORGANISM(S): Homo sapiens

PROVIDER: GSE283225 | GEO | 2025/04/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2017-06-29 | PXD005753 | Pride
2023-05-16 | GSE150748 | GEO
2013-05-03 | E-GEOD-34721 | biostudies-arrayexpress
2013-05-03 | GSE34721 | GEO
2018-06-14 | PXD009803 | Pride
2022-08-15 | PXD034158 | Pride
2022-02-16 | PXD023221 | Pride
2020-04-07 | GSE148176 | GEO
2024-05-22 | GSE228254 | GEO
2018-09-29 | GSE109534 | GEO